吉西他滨联合顺铂新辅助化疗对膀胱癌根治术患者预后的影响

Effects of Gemcitabine Combined with Cisplatin Neoadjuvant Chemotherapy on Prognosis of Patients with Bladder Cancer

目的:探讨吉西他滨联合顺铂新辅助化疗对膀胱癌根治术患者预后的影响。方法:对某院2014年1月~2016年10月期间50例行膀胱癌根治术化疗患者的病历资料进行回顾性分析,将所有患者根据不同的化疗方法分为对照组和研究组,每组25例,对照组患者第1d、第15d、第22d给予甲氨蝶呤和长春花碱静脉滴注,第2d给予阿霉素和顺铂静脉滴注,1个周期为22d;研究组患者第1d、第8d给予吉西他滨与顺铂静脉滴注,1个周期为21d。观察两组患者治疗后的预后、复发及不良反应发生情况。结果:研究组患者术后降期率为64.00%,对照组患者术后降期率为32.00%,两组比较差异性显著(P<0.05);研究组死亡率及复发率显著低于对照组,生存时间显著长于对照组,两组比较差异性显著(P<0.05);两组不良反应发生情况比较无显著性差异(P>0.05)。结论:吉西他滨联合顺铂新辅助化疗可有效降低肿瘤分期及复发,改善预后,延长患者的生存期,值得临床进行推广应用。

Objective：To investigate the effect of gemcitabine combined with cisplatin neoadjuvant chemotherapy on the prognosis of radical resection of bladder cancer.Methods：A retrospective analysis was made on the medical records of 50 patients undergoing radical mastectomy from January 2014 to October 2016.All patients were divided into control group and study group according to different chemotherapy methods with 25 cases in each group.On the 1st d,15 th d and 22 nd d,the control group was given methotrexate and vinca intravenous infusion,on the first 2d given doxorubicin and cisplatin intravenous infusion,a cycle of 22 d.In the study group,gemcitabine and cisplatin were given intravenous infusion on the 1st d and 8th d,with a cycle of 21 days.Then compare the prognosis,recurrence and adverse events were observed after treatment of the two groups.Results：The postoperative reduction rate was 64.00% in the study group and 32.00% in the control group.The difference between the two groups was significant（P〈0.05）.The mortality and recurrence rate in the study group were significantly lower than those in the control group（P〈0.05）.There was no significant difference in adverse reactions between the two groups（P〉0.05）.Conclusion：Gemcitabine combined with cisplatin neoadjuvant chemotherapy can effectively reduce tumor staging and recurrence,improve the prognosis and prolong the survival of patients,which is worthy of clinical application.